<DOC>
	<DOCNO>NCT00371748</DOCNO>
	<brief_summary>TAXUS ATLAS Small Vessel global , multi-center , single-arm , trial patient coronary artery less 2.5 mm diameter treat TAXUS Liberté stent versus historical TAXUS Express control derive subset lesion-matched TAXUS V patient treat 2.25 mm stent . The objective study evaluate clinical angiographic outcome TAXUS Liberté-SR 2.25 mm stent de novo lesion . The hypothesis TAXUS Liberté-SR stent non-inferior safety efficacy TAXUS Express-SR stent treatment de novo lesion small coronary vessel .</brief_summary>
	<brief_title>A Study TAXUS Liberté Stent Treatment de Novo Coronary Artery Lesions Small Vessels</brief_title>
	<detailed_description>TAXUS ATLAS Small Vessel global , multi-center , single-arm , trial patient receive TAXUS Liberté-SR 2.25 mm paclitaxel-eluting stent . The result compare two different historical control group . The first control group consist subset lesion-matched TAXUS V patient treat 2.25 mm TAXUS Express-SR paclitaxel-eluting stent . The objective analysis evaluate clinical angiographic outcome TAXUS Liberté-SR 2.25 mm stent de novo lesion versus TAXUS Express-SR stent . The hypothesis TAXUS Liberté-SR stent non-inferior safety efficacy TAXUS Express-SR stent treatment de novo lesion small coronary vessel . The second control group consist subset lesion-matched TAXUS V patient treat either 2.5 mm 2.25 mm bare metal Express stent . The objective analysis evaluate clinical angiographic outcome TAXUS Liberté-SR 2.25 mm stent de novo lesion versus Express bare metal stent . The hypothesis TAXUS Liberté-SR stent superior safety efficacy Express bare metal stent treatment de novo lesion small coronary vessel .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>General 1 . Patient least 18 year old . 2 . Eligible percutaneous coronary intervention ( PCI ) 3 . Documented stable angina pectoris unstable angina pectoris document ischemia , document silent ischemia 4 . Left ventricular ejection fraction ( LVEF ) least 25 % 5 . Acceptable candidate coronary artery bypass grafting ( CABG ) 6 . Patient legal guardian understands study requirement treatment procedure provide write Informed Consent studyspecific test procedure perform 7 . Willing comply specify followup evaluation Angiographic 1 . Only one lesion ( target lesion ) may treat study stent.However , one additional lesion nontarget vessel may treat index procedure commercially avaiable bare metal stent , heparincoated stent TAXUS Express stent . 2 . Successful predilation mandatory entry study 3 . Target lesion locate within single native coronary artery 4 . Target lesion enrol treatment may compose multiple lesion ( 10mm diseased segment ) must completely cover one study stent . 5 . Cumulative target lesion length great equal 10 mm less equal 28 mm ( visual estimate ) 6 . Target lesion RVD 2.25 mm [ 2.2 2.5 mm ( visual estimate ) ] 7 . Target lesion diameter stenosis least 50 % ( visual estimate ) 8 . Target lesion de novo ( i.e. , coronary lesion previously treat ) General 1 . Known hypersensitivity paclitaxel 2 . Any previous , concurrent plan treatment nonstudy antirestenotic drugcoated drugeluting coronary stent . 3 . Planned use study stent nonstudy stent ( i.e. , commercial stent ) treatment target vessel 4 . Previous plan treatment intravascular brachytherapy target vessel 5 . Planned CABG within 9months postindex procedure 6 . MI within 72 hour prior index procedure and/or creatine kinase ( CK ) &gt; 2x local laboratory 's ULN unless CKMB &lt; 2x ULN 7 . Cerebrovascular Accident ( CVA ) within past 6 month 8 . Cardiogenic Shock 9 . Acute chronic renal dysfunction 10 . Contraindication ASA , clopidogrel ticlopidine 11 . Leukopenia 12 . Thrombocytopenia thrombocytosis 13 . Active peptic ulcer active gastrointestinal ( GI ) bleed 14 . Known allergy stainless steel 15 . Any prior true anaphylactic reaction contrast agent 16 . Patient currently , treat paclitaxel chemotherapeutic agent within 12months index procedure 17 . Anticipated treatment paclitaxel oral rapamycin period 9months index procedure 18 . Male female know intention procreate within 3 month index procedure 19 . Female childbearing potential positive pregnancy test within 7 day index procedure , lactate 20 . Life expectancy le 24 month due medical condition 21 . Comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study 22 . Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study Angiographic 1 . Unprotected protected leave main coronary artery disease ( patient protect leave main disease enrol ONLY target lesion RCA ) 2 . Target lesion ostial location ( within 3.0 mm vessel origin ) 3 . Target lesion and/or target vessel proximal target lesion moderately severely calcified visual estimate 4 . Target lesion and/or target vessel proximal target lesion tortuous 5 . Target lesion locate within distal &gt; 60 degree bend vessel 6 . Target lesion involve bifurcation side branch vessel &gt; 1.5 mm ( visual estimate ) 7 . Target lesion totally occlude ( TIMI flow &lt; 1 ) , either baseline predilation 8 . Angiographic presence probable definite thrombus 9 . Pretreatment teh target vessel index procedure allow device except predilation balloon angioplasty cut balloon 10 . A previously treat lesion within target vessel : &lt; 15mm target lesion ( visual estimate ) Performed &lt; /= 6 month index procedure &gt; 30 % residual stenosis previous treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>